NewAmsterdam Pharma Company N.V. (NAMSW)
NAMSW Stock Price Chart
Explore NewAmsterdam Pharma Company N.V. interactive price chart. Choose custom timeframes to analyze NAMSW price movements and trends.
NAMSW Company Profile
Discover essential business fundamentals and corporate details for NewAmsterdam Pharma Company N.V. (NAMSW) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
10 Feb 2021
Employees
68.00
CEO
Michael Harvey Davidson Facp.
Description
NewAmsterdam Pharma Company N.V. is a biopharmaceutical firm currently in the clinical development phase, committed to enhancing therapeutic options for individuals living with metabolic diseases. The company's primary experimental treatment, obicetrapib, is an innovative, selective agent designed to inhibit Cholesteryl Ester Transfer Protein (CETP). Clinical trials have shown this compound to be effective in both lowering "bad" low-density lipoprotein cholesterol (LDL-C) and significantly elevating "good" high-density lipoprotein cholesterol (HDL-C) simultaneously. Founded in 2019, this Dutch company maintains its headquarters in Naarden.
NAMSW Financial Timeline
Browse a chronological timeline of NewAmsterdam Pharma Company N.V. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Aug 2026
EPS estimate is -$0.48, while revenue estimate is $1.79m.
Earnings released on 7 May 2026
EPS came in at -$0.40 surpassing the estimated -$0.46 by +12.85%, while revenue for the quarter reached $3.04m , beating expectations by +74.25%.
Earnings released on 18 Feb 2026
EPS came in at -$0.62 falling short of the estimated -$0.45 by -36.64%, while revenue for the quarter reached $32.00k , missing expectations by -98.89%.
Earnings released on 5 Nov 2025
EPS came in at -$0.61 falling short of the estimated -$0.39 by -54.77%, while revenue for the quarter reached $348.00k , missing expectations by -93.44%.
Earnings released on 6 Aug 2025
EPS came in at -$0.18 surpassing the estimated -$0.46 by +60.27%, while revenue for the quarter reached $19.15m , beating expectations by +447.99%.
Earnings released on 8 May 2025
EPS came in at -$0.46 surpassing the estimated -$0.49 by +6.66%, while revenue for the quarter reached $3.26m , beating expectations by +108.73%.
Earnings released on 26 Feb 2025
EPS came in at -$0.98 falling short of the estimated -$0.49 by -102.33%, while revenue for the quarter reached $13.23m , beating expectations by +653.31%.
Earnings released on 6 Nov 2024
EPS came in at -$0.19 surpassing the estimated -$0.50 by +61.40%, while revenue for the quarter reached $31.93m , beating expectations by +1.61k%.
Earnings released on 7 Aug 2024
EPS came in at -$0.41 surpassing the estimated -$0.58 by +28.33%, while revenue for the quarter reached $2.29m , beating expectations by +89.67%.
Earnings released on 8 May 2024
EPS came in at -$1.14 falling short of the estimated -$0.62 by -83.87%, while revenue for the quarter reached $1.39m , missing expectations by -13.85%.
Earnings released on 28 Feb 2024
EPS came in at -$0.57 , while revenue for the quarter reached $1.75m .
Earnings released on 30 Sept 2023
EPS came in at -$0.59 , while revenue for the quarter reached $1.98m .
Earnings released on 7 Aug 2023
EPS came in at -$0.52 , while revenue for the quarter reached $8.65m .
Earnings released on 7 Aug 2023
EPS came in at -$0.47 , while revenue for the quarter reached $1.72m .
Earnings released on 31 Mar 2023
EPS came in at -$2.37 , while revenue for the quarter reached $1.49m .
Earnings released on 28 Nov 2022
EPS came in at -$2.14 , while revenue for the quarter reached $5.49m .
Earnings released on 30 Jun 2022
EPS came in at $1.61 , while revenue for the quarter reached $48.90m .
Earnings released on 30 Mar 2022
EPS came in at $1.70 , while revenue for the quarter reached $51.71m .
Earnings released on 31 Dec 2021
EPS came in at -$1.13 .
Earnings released on 30 Sept 2021
EPS came in at -$0.63 .
NAMSW Stock Performance
Access detailed NAMSW performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
